–29.78% since Feb. 19
Abbott (NYSE:ABT) received FDA emergency use authorization last week for a molecular test to detect the coronavirus. The Abbott Park, Ill.-based company said it will immediately ship 150,000 of its RealTime SARS-CoV-2 EUA tests to existing U.S customers.
Customers can use the tests on Abbott’s m2000 RealTime system, and Abbott will deploy additional m2000 systems as needed. The more than 175 m2000 systems in the U.S. are able to run up to 470 tests in 24 hours. Abbott has a goal of eventually providing up to 1 million coronavirus tests per week.